1:25 PM
 | 
Nov 10, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Novartis reports final Phase III data of Gilenya in pediatric MS

Novartis AG (NYSE:NVS; SIX:NOVN) reported final data from the Phase III PARADIGMS trial in 215 patients ages 10-17 with multiple sclerosis showing that once-daily oral Gilenya (Imusera) fingolimod (FTY720) reduced annualized relapse rate (ARR) over 2 years, the primary endpoint, by 82% vs. once-weekly intramuscular Avonex interferon beta-1a. Novartis previously reported that Gilenya met the...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >